surmount-1 trial tirzepatide obesity without diabetes (ZEPBOUND) Approved for Chronic Weight Management in Adults with ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Tirzepatide for the Maintenance of

This educational protocol presents a oncedaily subcutaneous approach for all vial sizes with practical reconstitution for insulinsyringe measurements

FDA Information on Mounjaro Mounjaro Drug Information for the official FDA label, including clinical trial results and safety details

Meet our doctors Last reviewed: 04 Aug 2025 Sources Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison (2022) Diabetes Obesity & Metabolism [accessed 15 June 2025] MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss (2023) Gov.uk [accessed 15 June 2025] Mounjaro (2023) Mounjaro [accessed 15 June 2025] Mounjaro KwikPen 2.5/5/7.5/10/12.5/15 mg solution for injection in pre-filled pen (2024) EMC [accessed 15 June 2025] Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial (2018) The Lancet [accessed 15 June 2025] Weight loss injections NHS weight loss injections GLP-1 for weight loss Can doctors help with weight loss

Make sure a clinician reviews your request Your health is taken very seriously, which is why our UK-approved prescribers review every message and request that you submit

Your dose may have been optimized during these months, reaching a therapeutic level where appetite control feels natural and side effects remain manageable

Diastolic blood pressure was significantly reduced in Study 1 but not in Study 2